TERMINATION AGREEMENT dated as of June 14, 2011 by and among ADOLOR CORPORATION and GLAXO GROUP LIMITED and GLAXOSMITHKLINE LLCTermination Agreement • August 3rd, 2011 • Adolor Corp • Pharmaceutical preparations • Delaware
This TERMINATION AGREEMENT (“Agreement”) dated as of June 14, 2011, is made by and among ADOLOR CORPORATION, a Delaware corporation, having its principal office at 700 Pennsylvania Drive, Exton, Pennsylvania 19341, United States (“Adolor”), GLAXO GROUP LIMITED, a United Kingdom corporation, having its principal office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, United Kingdom (“GSK”), and GlaxoSmithKline LLC (formerly known as SmithKline Beecham Corporation d/b/a GlaxoSmithKline), a Delaware limited liability company, having its principle office at One Franklin Plaza, Philadelphia, Pennsylvania, 19101, United States (“GSK LLC,” and together with GSK, the “GSK Entities”). Adolor, GSK and GSK LLC each may be referred to as a “Party” or together, the “Parties”.
AMENDMENT NO. 6 TO COLLABORATION AGREEMENTCollaboration Agreement • August 3rd, 2011 • Adolor Corp • Pharmaceutical preparations
THIS AMENDMENT NO. 6 TO COLLABORATION AGREEMENT (this “Amendment No. 6”, dated as of June 14, 2011 (the “Effective Date”), is made by and between ADOLOR CORPORATION, a Delaware corporation having its principal office at 700 Pennsylvania Drive, Exton, Pennsylvania 19341 (“Adolor”), and GLAXO GROUP LIMITED, a United Kingdom corporation having its principal office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, United Kingdom (“GSK”). Adolor and GSK are each sometimes referred to individually as a “Party” and together as the “Parties.”
